Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Anteo Diagnostics To Develop Consumable Products With SCIENION

Anteo Diagnostics (ASX:ADO) has partnered with Germany's SCIENION to co-develop protein microarray diagnostic consumables using Anteo's proprietary Mix&Go™ technology.

The first targeted products will be activated glass and polymer slides.

Anteo will combine its Mix&Go activated surface consumables, which improve functionality and stability of biological molecules, with SCIENION's precision spotting sciFLEXARRAYER technology.

This will deliver more accurate results and better, longer-lasting and more cost effective diagnostics.

SCIENION provides systems and services for the contact-free printing of biological and chemical agents for diagnostics, pharmaceutics, veterinary, plant and food analytics and research.

Josh Soldo, Anteo vice president scientific affairs, explained:

"With SCIENION, we have found a partner with deep expertise in surface functionalization and protein spotting, and one with excellent products.

"As a result of our partnership, scientists will soon have the tools that they need to overcome the present limitations of protein arrays, and increase the performance of their arrays, while reducing the sample size needed to get results.

"In brief, we expect the partnership to yield more effective tests with better specificity."

Holger Eickhoff, SCIENION chief executive officer, added:

"Anteo's new coating technology will enable us to provide an even higher level of customer application support via unprecedented combinations of materials, surfaces and deposition technology.

"The perfect pairing of the right surface with the right dispensing is key to a successful application where a biological molecule is deposited to become attached to a surface. The expertise of both companies is very complementary, and together we will exploit the resulting synergies."


Mix&Go is the healthcare application for Anteo's nanoglue technology.

It uses coordination chemistry (rather than covalent chemistry or passive binding) for gentle and secure multipoint binding of biomolecules to synthetic surfaces.

This offers ease of use, increased antibody functionality and decreased background interference.

Assays produced using Mix&Go can result in reduced development costs and improvements to medical devices and in-vitro diagnostic methods, leading to the earlier detection of disease.


The momentum is building for Mark Bouris chaired Anteo as its Mix&Go molecular glue product range continues to draw attention from major players in the industry.

Partnering with SCIENION could lead to the development of products that will further build sales for the company.

It also follows on the agreement last week for Anteo's products to be offered through Sigma-Aldrich Corporation's (NASDAQ:SIAL) network and online catalog, exposing them to more than 1.4 million scientists and technologists.

We would expect additional news and announcements to flow from companies wanting to access Anteo's Mix&Go products in a variety of fields of applications.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.